Rewatch the Breast Cancer Debate of the Year
Breast Cancer Debate of the Year
On Friday 27 January 2023, the Institute Jules Bordet and the Belgian Society of Medical Oncology (BSMO) represented by its Breast Cancer Task Force organised the “Breast Cancer Debate of the Year”. The Friday evening session included debates of great interest for clinical practice as well as educational lectures. You can rewatch the lectures and download the presentations here below.
Session 1:
Are antracyclines still needed in luminal early disease?
Are antracyclines still needed in luminal early disease? Prof. Hannelore Denys says yes, while prof. Hans Wildiers is not in favour.
Session 2:
Ovarian function suppression and aromatase inhibitor can replace adjuvant chemotherapy ...
A pro and contra discussion between prof. Patrick Neven and prof. Guy Jerusalem on the subject: ovarian function suppression and aromatase inhibitor can replace adjuvant chemotherapy.
Session 3:
What treatment in residual disease following neoadjuvant chemotherapy for stage III poorly differentiated luminal breast cancer?
Prof. François Duhoux elaborates on treatment options in residual disease following neoadjuvant chemotherapy for stage III poorly differentiated luminal breast cancer.
Session 4:
Treatment of luminal MBC after exposure to CDK4/6 inhibitors
Prof. Ahmad Awada presents a clinical case study to explain the treatment of luminal MBC after exposure to CDK4/6 inhibitors.